Equities research analysts at UBS AG (NYSE: UBS) lifted their price target on shares of CVS Caremark (NYSE: CVS) from $49.00 to $53.00 in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the stock.
A number of other firms have also recently commented on CVS. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of CVS Caremark to $52.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of CVS Caremark from $48.00 to $50.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at BMO Capital Markets downgraded shares of CVS Caremark from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, March 13rd. They now have a $47.00 price target on the stock.
CVS Caremark opened at 46.14 on Thursday. CVS Caremark has a 1-year low of $31.30 and a 1-year high of $46.22. The company has a market cap of $60.092 billion and a price-to-earnings ratio of 17.97.
The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.65 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.63 EPS by $0.02. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Analysts expect that CVS Caremark will post $0.83 EPS next quarter.
CVS Caremark Corporation (CVS Caremark) is a pharmacy healthcare provider in the United States. It provides pharmacy services through its pharmacy benefit management (PBM) mail order and specialty pharmacy division, Caremark Pharmacy Services; approximately 7,000 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and through its online pharmacy, CVS.